Brokerages Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Price Target at $76.50

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have earned a consensus recommendation of “Hold” from the seven ratings firms that are covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $76.50.

PBH has been the topic of a number of analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Jefferies Financial Group reduced their target price on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th.

Insider Activity at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the sale, the vice president owned 41,048 shares in the company, valued at $2,706,294.64. This trade represents a 2.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Institutional investors have recently modified their holdings of the company. UMB Bank n.a. grew its holdings in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after purchasing an additional 219 shares during the last quarter. Bayforest Capital Ltd purchased a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $29,000. First Horizon Corp purchased a new stake in shares of Prestige Consumer Healthcare in the third quarter valued at about $32,000. Barrow Hanley Mewhinney & Strauss LLC grew its position in shares of Prestige Consumer Healthcare by 106.8% in the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after purchasing an additional 283 shares during the last quarter. Finally, Torren Management LLC acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $35,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $59.24 on Friday. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. The company has a market cap of $2.80 billion, a P/E ratio of 15.67, a PEG ratio of 1.84 and a beta of 0.41. Prestige Consumer Healthcare has a 52 week low of $57.25 and a 52 week high of $89.37. The company has a 50-day moving average price of $65.18 and a 200 day moving average price of $63.03.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.16 by ($0.02). The business had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The business’s revenue for the quarter was down 2.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Research analysts predict that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).